Akero leaps on statistically-significant MASH outcomes with efruxifermin

4 March 2024

US clinical-stage biotech Akero Therapeutics’ (Nasdaq: AKRO) shares soared 54% to $42.80 in pre-market activity today, after it released new data on its metabolic-associated steatohepatitis (MASH) candidate.

Akero reported statistically-significant histological improvements at Week 96 in the Phase IIb HARMONY study evaluating the efficacy and safety of its lead candidate efruxifermin (EFX) in patients with pre-cirrhotic MASH, fibrosis stage 2 or 3 (F2-F3).

This marks a change of fortunes, as last October the Phase IIb SYMMETRY clinical trial of EFX failed to demonstrate statistically-significant benefit at 36 weeks.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK